Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

— HYPO-HEART  

Official title:

Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03150030
• Other study ID #: H-16046212
• Status: Completed
• Start date: February 1, 2017
• Est. completion date: January 6, 2020

Study information

• Verified date: October 2020
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Twenty-one patients with insulin-treated type 2 diabetes with diabetic complications will be recruited to Part 1 of the study, a three-hour combined hyper- and hypoglycaemic clamp, along with a control group of twenty-one individuals with normal glucose tolerance matched for age, gender, and body mass index. Patients with type 2 diabetes will be scheduled for a three-week run-in period with LR and CGM prior to participation in Part 1. Only patients with a well-functioning loop-recorder and who can comply with CGM will be included. Patients with type 2 diabetes will continue in part 2 of the study, a one year observational study employing CGM and LR and clinical examination after 1, 3, 6, 9, and 12 months and an extended observation period of 2 years employing LR and clinical examination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 6, 2020
• Est. primary completion date: January 6, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Patients with type 2 diabetes

• Informed and written consent
• Type 2 diabetes diagnosed according to the criteria of the World Health Organization (WHO)
• Treatment with insulin
• Glycated haemoglobin A1c (HbA1c) =58 mmol/mol
• One or more clinical relevant complications to diabetes defined as: peripheral neuropathy with vibration perception threshold of > 25 volt determined by biothesiometry, moderate to severe retinopathy, nephropathy (creatinine >130 µmol/l and/or albuminuria), and/or macrovascular disease. Macrovascular disease is defined as coronary disease (stable angina pectoris or previous unstable angina pectoris or myocardial infarct), cerebrovascular disease (previous stroke or transitional cerebral ischaemia), and peripheral vascular disease (previous intermittent claudication or prior acute ischemia)
• Well-functioning LR during run-in period (acceptable readings judged by an arrhythmologist)
• Participation in the extended study Healthy individuals
• HbA1c =42 mmol/mol
• Fasting plasma glucose =6.1 mmol/l Exclusion Criteria: Patients with type 2 diabetes
• Arrhythmia diagnosed prior to or at the time of inclusion
• Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion
• Severe heart failure (left ventricular ejection fraction <25%)
• Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• Insulin naïve patients with type 2 diabetes
• Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema)
• Unable to comply with daily CGM during run-in period
• Anemia (male: hemoglobin < 8.0; female: hemoglobin < 7.0 mmol/l) Healthy individuals
• Type 1 or type 2 diabetes
• Prediabetes (HbA1c >42 mmol/l and/or fasting plasma glucose >6.1 mmol/l)
• Family history of diabetes (type 1 og type 2 diabetes)
• Arrhythmia diagnosed prior to or at the time of inclusion
• ICD or pacemaker at the time of inclusion
• Severe heart failure (left ventricular ejection fraction <25%)
• Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema)
• Anemia (male: hemoglobin < 8.0; female: hemoglobin < 7.0 mmol/l)

Related Conditions & MeSH terms

• Arrhythmia, Cardiac
• Arrhythmias, Cardiac
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Hypoglycemia

Intervention

Other:
• Combined hyper- and hypoglycaemic clamp
During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.

Device:
• Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)
Implantation of a loop-recorder
• Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)
Monitoring with a continuous glucose monitor

Locations

Country	Name	City	State
Denmark	Gentofte Hospital	Hellerup

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Gentofte, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Clinically relevant arrhythmias	Composite endpoint including atrial fibrillation, brady-arrhythmias and tachy-arrhythmias. Clinically relevant brady-arrhythmias are defined as sinus arrest for more than 3 seconds, frequency below 30 beats per minute (bpm), or high grade atrioventricular (AV) block including Mobitz Type II and third-degree AV block. Clinically relevant tachy-arrhythmias are defined as sustained ventricular tachycardia (duration >30 seconds), and non-sustained ventricular tachycardia.	0-240 min during the combined hyper- and hypoglycaemic clamp
Primary	Part 2: Prevalence of clinically relevant arrhythmias as defined above	Prevalence of clinically relevant arrhythmias as defined above	Within 12 months
Primary	Part 2: Clinically relevant arrhythmias during hypoglycaemia compared to euglycaemia	Clinically relevant arrhythmias during hypoglycaemia compared to euglycaemia	Within 12 months
Primary	Part 2: Difference in MAGE	Difference in mean amplitude of glycaemic excursions (MAGE) two hours preceding an arrhythmic event versus MAGE during non-event	Within 12 months
Secondary	Part 1: Differences in mean corrected QT interval (QTc)	Differences in mean corrected QT interval (QTc) between patients with type 2 diabetes and matched normal glucose tolerant individuals during the combined hyper- and hypoglycaemic clamp	0-240 min during the combined hyper- and hypoglycaemic clamp
Secondary	Part 1: Difference in counter regulatory hormonal response	Difference in counter regulatory hormonal response between patients with type 2 diabetes and matched normal glucose tolerant individuals during the combined hyper- and hypoglycaemic clamp	0-240 min during the combined hyper- and hypoglycaemic clamp
Secondary	Part 1: Differences in haemodynamic regulation	Differences in haemodynamic regulation (measured by echocardiography) between patients with type 2 diabetes and matched normal glucose tolerant individuals during a combined hyper- and hypoglycaemic clamp	0-240 min during the combined hyper- and hypoglycaemic clamp
Secondary	Part 2: Clinical relevant arrhythmias during low glucose variability compared to high glucose variability.	Clinical relevant arrhythmias during low glucose variability (LGV), defined as variations in plasma glucose below or equal to 5 mmol/l within two hours preceding an arrhythmic event, compared to high glucose variability (HGV), defined as variations in plasma glucose above 5 mmol/l within two hours preceding an arrhythmic event	Within 12 months
Secondary	Part 2: The relationship between cardiovascular disease at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	The relationship between cardiovascular disease (heart failure and ischaemic heart disease) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	Within 12 months
Secondary	Part 2: The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	Within 12 months
Secondary	Part 2: The relationship between diabetes complication status at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	The relationship between diabetes complication status (neuropathy, nephropathy, retinopathy) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV	Within 12 months
Secondary	Part 2: Correlation between prevalence and total duration of hypoglycaemia and risk of clinically relevant arrhythmias	Correlation between prevalence and total duration of hypoglycaemia and risk of clinically relevant arrhythmias	Within 12 months
Secondary	Part 2: Correlation between plasma glucose variation and risk of clinical relevant arrhythmias	Correlation between plasma glucose variation (variation in plasma glucose (? mmol/l) within two hours of the event) and risk of clinical relevant arrhythmias	Within 12 months